Fulcrum Therapeutics Stock Price, News & Analysis

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company focused on genetically defined rare diseases, announced its participation in key investor conferences. Management will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 4:15 p.m. ET, followed by the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET, and the Cantor Virtual Global Healthcare Conference on September 28, 2021, at 3:20 p.m. ET. Live audio webcasts will be accessible on Fulcrum's Investor Relations page.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced the closing of its public offering of 7,590,000 shares at $19.00 each, raising $144.2 million in gross proceeds. The offering included 990,000 shares purchased at the underwriters' exercise option. The shares were sold under a previously effective SEC registration statement. SVB Leerink, Piper Sandler & Co., and Stifel served as joint bookrunning managers, while H.C. Wainwright & Co. led the offering management. The funds will support Fulcrum's ongoing clinical development of therapeutics for genetically defined rare diseases.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC) has announced the pricing of a public offering of 6,600,000 shares of its common stock at $19.00 per share, aiming for total gross proceeds of approximately $125 million before expenses. The offering is expected to close on August 16, 2021. Additionally, underwriters have a 30-day option to purchase up to 990,000 extra shares. The offering is being conducted under a shelf registration statement and involves joint bookrunning managers SVB Leerink, Piper Sandler & Co., and Stifel.

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, has announced a public offering of $100 million in common stock, with an option for underwriters to purchase an additional $15 million. The offering is managed by SVB Leerink, Piper Sandler & Co., and Stifel. Fulcrum plans to use the proceeds to advance its clinical development programs, including drugs for rare diseases. The offering is subject to market conditions and follows a previously filed shelf registration with the SEC.

Fulcrum Therapeutics reported positive interim results from a Phase 1 trial with FTX-6058 for sickle cell disease, demonstrating proof of mechanism and biology. The company plans a Phase 1b trial in sickle cell patients in Q4 2021. Financially, Fulcrum's cash and equivalents rose to $125.6 million by June 30, 2021, supporting operations into Q1 2023. Collaboration revenue increased to $4.4 million, while net loss for Q2 2021 was $19.6 million. The firm remains focused on advancing therapies for rare genetic diseases.

Fulcrum Therapeutics (Nasdaq: FULC) announced positive interim results from its Phase 1 trial of FTX-6058, showing a mean 4.5-fold induction of HBG mRNA and a 4.2-fold increase in F-reticulocytes at the 10mg dose after 14 days. The investigational drug, targeting hemoglobinopathies, was well tolerated with no serious adverse events reported. The company plans to initiate a Phase 1b trial in sickle cell patients by Q4 2021 and submit an IND application for non-sickle cell hemoglobinopathies by year-end 2021, highlighting a potential advancement in treatment options.

Fulcrum Therapeutics (Nasdaq: FULC) announced it will release its second quarter 2021 financial results on August 10, 2021, prior to market open. A conference call and webcast are scheduled for 8:00 a.m. ET to discuss the results and recent corporate developments. The company specializes in developing treatments for genetically defined rare diseases. It has advanced losmapimod into Phase 2 clinical trials for facioscapulohumeral dystrophy and FTX-6058 into Phase 1 clinical trials for sickle cell disease and beta-thalassemia.

Fulcrum Therapeutics (NASDAQ: FULC) announced results from its Phase 2b ReDUX4 trial of losmapimod for facioscapulohumeral muscular dystrophy (FSHD). While the primary endpoint of DUX4-driven gene expression was not met, significant clinical benefits were observed, including reduced muscle fat infiltration and improved functional outcomes. Losmapimod was well tolerated, with no serious adverse events related to treatment. The company plans to engage with the FDA regarding future regulatory steps in H2 2021. Overall, these results support losmapimod as a potential transformative therapy for FSHD.

Fulcrum Therapeutics (Nasdaq: FULC) will hold a conference call on June 24, 2021, at 8:00 am ET to discuss the results of the Phase 2b ReDUX4 trial involving losmapimod for treating facioscapulohumeral muscular dystrophy (FSHD). The company is presenting multiple findings at the 28th Annual FSHD Society International Research Congress. These include efficacy and safety data from the trial. FSHD affects 16,000 to 38,000 patients in the U.S., with no approved treatments available. Losmapimod has received FDA Fast Track designation.